Live Breaking News & Updates on Ovaxin doses

Stay informed with the latest breaking news from Ovaxin doses on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Ovaxin doses and stay connected to the pulse of your community

COVID-19: Same vaccine to be administered as precaution dose, confirms Govt

This means that those who took Covishield will take Covishield again and those who were given the Covaxin jab, will get a third dose of Covaxin.

Hyderabad , Andhra-pradesh , India , Bharat , Narendra-modi , Mansukh-mandaviya , Centre-on , Union-health , Twitter , Serum-institute-of-india , Pune-based-serum-institute , Prime-minister-narendra-modi

DNA Explainer: What happens when there is mix-match of Covaxin and Covishield?

DNA Explainer: What happens when there is mix-match of Covaxin and Covishield? - Study conducted by AIG Hospitals with Asian Healthcare Foundation researchers showed mixing Covishield and Covaxin doses is four times more effective.

D-nageshwar-reddy , Indian-council-for-medical-research , Asian-healthcare-foundation , Second-dose , Indian-council , Medical-research , Dna-explainer , Accine-mixing , Ovaxin-doses , Ovishield-doses , Ovid-19-vaccine-booster , Ig

11 crore people overdue for second dose of COVID-19 vaccine, shows government data

11 crore people overdue for second dose of COVID-19 vaccine, shows government data - UP, MP, Rajasthan, Maharashtra and Bihar together account for around 49% of such beneficiaries who are long due for taking the second dose of vaccine.

Madhya-pradesh , India , Uttar-pradesh , Bihar , Mansukh-mandaviya , Union-territories , Union-health-ministry , Union-health , Health-ministry , Wednesday-union-health-minister-mansukh-mandaviya , India-covid-19-vaccination-drive , Econd-dose-of-vaccination

Centre received 65.25 crore Covishield doses, 9.1 crore Covaxin doses till September 19

The Government of India received over 65.25 crore Covishield doses from Serum Institute of India and 9.1 crore doses of Covaxin from Bharat Biotech till September 19.

India , Pune , Maharashtra , Bharat , Prakash-kumar-singh , Mansukh-mandaviya , Union-health , Union-ministry-of-health , Serum-institute , Serum-institute-of-india , Bharat-biotech , Union-ministry

Kerala man files plea in court for Covishield after taking both doses of Covaxin

Kerala man files plea in court for Covishield after taking both doses of Covaxin, read why - The man Girikumar, 50 had filed a plea in the Kerala High Court stating that he works in Saudi Arabia which is yet to recognise the Covaxin.

Saudi-arabia , Kannur , Kerala , India , Saudi , Kerala-high-court , Bharat-biotech , சவுதி-அரேபியா , கண்ணூர் , கேரள , இந்தியா

Covaxin reached 30 cities in 30 days amid staff shortages : Bharat Biotech

URL copied
Covaxin has reached 30 cities in the past 30 days
Covaxin, India's indigenous Covid-19 vaccine, has reached 30 cities in the past 30 days, said the vaccine manufacturer Bharat Biotech in a statement on Tuesday. Among 30 cities that have received the Covaxin doses include Delhi, Kolkata, Mumbai, Chennai, Bengaluru, Kochi and Amritsar.
Covaxin is one of the three vaccines that the DGCI has cleared for emergency use in India. The two others are Covishield and Sputnik V. While Covishield is the local version of Oxford-AstraZeneca COVID-19 vaccine and being manufactured by Pune-based Serum Institute of India, Sputnik V is a Russian drug.

Mumbai , Maharashtra , India , Hyderabad , Andhra-pradesh , United-states , Amritsar , Punjab , Kolkata , West-bengal , Ankleshwar , Gujarat

WHO Covaxin emergency use approval expected in July September Bharat Biotech latest news

URL copied
Bharat Biotech expects EUL from WHO for Covaxin in July- September
Bharat Biotech on Tuesday said it expects approval for its COVID-19 vaccine Covaxin from the World Health Organisation for Emergency Use Listing (EUL) during July-September. The company said regulatory approvals for Covaxin are in process in more than 60 countries including the USA, Brazil
and Hungary among others.
"Application for EUL has been submitted to WHO-Geneva. Regulatory approvals are expected during July-September 2021," it said in a release.
Emergency Use Listing (EUL) is a procedure to streamline the process by which new or unlicensed products can be used during public health emergencies, according to WHO guidelines.

United-states , India , Hungary , Brazil , Bharat , World-health-organisation-for-emergency-use-listing , Bharat-biotech-international-limited , Drug-administration , Bharat-biotech , Image-source , World-health-organisation

Govt exploring possibility of Covaxin production outside India

URL copied
Govt exploring possibility of Covaxin production outside India
To address the shortage of COVID-19 jabs in the country, the government is exploring the possibility of boosting production of vaccines, including identifying manufacturing sites for indigenously developed Covaxin outside India, sources said. The government also intends to take up the matter with the World Health Organisation (WHO) to step up Covaxin production.
It will also take up with Moderna, Johnson and Johnson and other vaccine makers the issue of granting voluntary licence to third-party manufacturers in India on transfer of technology basis.
These issues were discussed in an inter-ministerial meeting on May 18 to deliberate upon the options, including voluntary licence, compulsory licence and government use authorisation under the Patents Act, 1970, available to increase the availability of drugs and vaccines used for treatment of COVID-19.

Bulandshahr , Uttar-pradesh , India , Karnataka , Mumbai , Maharashtra , Hyderabad , Andhra-pradesh , Zydus-cadila , Bharat-immunologicals , Hester-biosciences , Department-for-promotion-of-industry

Bharat Biotech's Karnataka facility to manufacture 5 crore Covaxin doses by August-end

URL copied
Bharat Biotech's Karnataka facility to manufacture 5 crore Covaxin doses by August-end
Bharat Biotech's Covaxin manufacturing facility that is under construction in Kolar district in Karnataka would have a manufacturing capacity of four to five crore doses a month by August-end, state Health Minister Dr K Sudhakar said on Monday.
Talking to reporters here ahead of his meeting with the experts on mucormycosis, known as as black fungus, which is emerging as a new threat to those who recover from COVID- 19, Sudhakar said he had a video conference with Bharat Biotech founder Dr Krishna Ella, his daughter Dr Jala Ella and rest of the team.

Bengaluru , Karnataka , India , Hyderabad , Andhra-pradesh , Malur , Bharat , Jala-ella , Narendra-modi , Krishna-ella , Image-source

'Extended gap between 2 doses of Covishield reasonable approach,' says US advisor Dr Fauci

'Extended gap between 2 doses of Covishield reasonable approach,' says US advisor Dr Fauci - "The fact that you delay it that long, it is very unlikely that it would have a negative effect on the efficacy of the vaccine," Fauci said.

New-york , United-states , India , White-house , District-of-columbia , Los-angeles , Anthony-fauci , Department-of-defense , Sputnikv-vaccine , United-state-that , Dr-fauci , Ovishield-vaccine-dose-gap